Wed. 27 Mar 2024, 7:34am ET
Benzinga
Earnings, News
Evaxion Biotech (NASDAQ:EVAX) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(1.60) by 90 percent. This is a 94.48 percent increase over losses of $(2.90) per share from the same period last year. The company reported $73.00 thousand in sales this quarter.